JPMorgan lowered the firm’s price target on Fresenius Medical to EUR 28 from EUR 32.10 and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FMS:
- Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter
- FMS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Fresenius Medical price target lowered to EUR 32.10 from EUR 38 at JPMorgan
- Fresenius Medical price target lowered to EUR 38 at Morgan Stanley
- Fresenius: GLP-1s slow CKD progression, mortality would decline, Reuters says